S. Damjanović

Assessment of p27 (cyclin‐dependent kinase inhibitor 1B) and aryl hydrocarbon receptor‐interacting protein (AIP) genes in multiple endocrine neoplasia (MEN1) syndrome patients without any detectable MEN1 gene mutations

R. Quinton, M. Korbonits, S. Akker, 2009, Clinical endocrinology.

Long-acting FC-fusion rhGH (GX-H9) shows potential for up to twice-monthly administration in GH-deficient adults.

Min Seon Kim, M. Ruchała, M. Bolanowski, 2018, European journal of endocrinology.

The results of molecular genetic testing for RET proto-oncogene mutations in patients with medullary thyroid carcinoma in a referral center after the two decade period.

M. Jovanovic, V. Živaljević, B. Rovčanin, 2016, Hippokratia.

Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms

D. Marković, V. Čokić, P. Milenković, 2015, Mediators of inflammation.

Significant Benefits of AIP Testing and Clinical Screening in Familial Isolated and Young-onset Pituitary Tumors

Julian R. E. Davis, H. Randeva, R. Eeles, 2020, The Journal of clinical endocrinology and metabolism.

Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10

Martin Fassnacht, Marta Barontini, Gabriela Sanso, 2011, Human mutation.

Prophylactic thyroidectomy for asymptomatic 3-year-old boy with positive multiple endocrine neoplasia type 2A mutation (codon 634).

S. Vujović, V. Živaljević, M. Tančić-Gajić, 2014, Srpski arhiv za celokupno lekarstvo.

Breast cancer in a patient with multiple endocrine neoplasia type 1 (MEN 1): A case report and review of the literature.

R. Dzodic, G. Pupić, Z. Inic, 2012 .

Genetic markers for head and neck cancers: Current state of art and perspectives

J. Dotlic, V. Djukic, P. Peško, 2003 .